While the addition of filibuvir to pegIFN/ribavirin improved on-treatment virologic response parameters , this did not translate into improved SVR rates due to a high rate of virologic relapse following completion of therapy ( @ mg : @ % ; @ mg : @ % ; placebo : @ % ) .